Evidence map›Paper›PMID 31337061›Full record

ArticlePharmaceutics2019

Anti-Angiogenic Effect of Orally Available Pemetrexed for Metronomic Chemotherapy.

Ruby Maharjan, Rudra Pangeni, Saurav Kumar Jha, Jeong Uk Choi, Kwan-Young Chang, Young Kweon Choi, Jin Woo Park, Youngro Byun

Open access · goldAbstract read
In one paragraph

Article in Pharmaceutics, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed
0.5field-weighted citation impact, top 35% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

6 citing papers in PubMed, 20 citations in OpenAlex.

  1. Article
  2. Review
  3. Article
  4. Article
  5. Article
  6. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 2 institutions in 1 country.

Ruby MaharjanResearch Institute of Pharmaceutical Sciences, College of Pharmacy, Seoul National University, Seoul 08826, Korea.
Rudra PangeniDepartment of Pharmacy, College of Pharmacy and Natural Medicine Research Institute, Mokpo National University, Muan-gun, Jeonnam 58554, Korea.ORCID 0000-0003-2025-676X
Saurav Kumar JhaDepartment of Pharmacy, College of Pharmacy and Natural Medicine Research Institute, Mokpo National University, Muan-gun, Jeonnam 58554, Korea.
Jeong Uk ChoiResearch Institute of Pharmaceutical Sciences, College of Pharmacy, Seoul National University, Seoul 08826, Korea.
Kwan-Young ChangIcure B&P, Global R&D center, Seoul 06649, Korea.
Young Kweon ChoiIcure B&P, Global R&D center, Seoul 06649, Korea.
Jin Woo ParkDepartment of Pharmacy, College of Pharmacy and Natural Medicine Research Institute, Mokpo National University, Muan-gun, Jeonnam 58554, Korea. jwpark@mokpo.ac.kr.
Youngro ByunDepartment of Molecular Medicine and Biopharmaceutical Science, Graduate School of Convergence Science and Technology, College of Pharmacy, Seoul National University, Seoul 08826, Korea. yrbyun@snu.ac.kr.
Mokpo National University · KRSeoul National University · KR

Funding

Bio & Medical Technology Development Program of the National Research Foundation (NRF) funded by the Korean Government Ministry of Science and ICT NRF-2017M3A9F5029655
6 · The paper itself

Abstract

Metronomic chemotherapy (MCT) is defined as the frequent administration of low-dose chemotherapeutics, without long drug-free periods, with the exertion of antitumor activity exclusively through anti-angiogenic mechanisms. In this study, we have developed an orally available formulation of pemetrexed (PMX) for MCT. PMX was first complexed ionically with

Indexed as

anti-angiogenesislow-dose therapymetronomic chemotherapyoral deliverypemetrexed

Identifiers

PMID31337061
PMCPMC6680992
OpenAlexW2960165302

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.